User:Mr. Ibrahem/Ivosidenib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Ivosidenib
Clinical data
Pronunciationeye"voe sid' e nib
Trade namesTibsovo
Other namesAG-120
AHFS/Drugs.comMonograph
MedlinePlusa618042
License data
Routes of
administration		By mouth
Drug classIsocitrate dehydrogenase-1 (IDH1) inhibitor[1]
Legal status
Legal status
Identifiers
  • (2S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3- difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine2-carboxamide
Chemical and physical data
FormulaC28H22ClF3N6O3
Molar mass582.97 g·mol−1
3D model (JSmol)
  • C1CC(=O)N(C1C(=O)N(C2=CC(=CN=C2)F)C(C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N

Ivosidenib, sold under the brand name Tibsovo, is a medication used to treat acute myeloid leukemia (AML) and cholangiocarcinoma.[2][3] Specifically it is used in cases with IDH1 mutations.[4][3] It is taken by mouth.[4]

Common side effects include diarrhea, tiredness, swelling, nausea, abdominal pain, shortness of breath, QT prolongation, neuropathy, liver problems, low potassium, and kidney problems.[4] Other side effects may include Guillain–Barré syndrome and differentiation syndrome.[4] Use during pregnancy may harm the baby.[4] It is a isocitrate dehydrogenase-1 (IDH1) inhibitor that works by decreasing abnormal production of 2-hydroxyglutarate (2-HG), leading to differentiation of cancer cells.[1]

Ivosidenib was approved for medical use in the United States in 2018.[4] As of 2021 it is not approved in Europe or the United Kingdom.[5] In the United States it costs about 30,000 USD per month as of 2021.[6]

References[edit]

  1. ^ a b "FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation". U.S. Food and Drug Administration (FDA) (Press release). 20 July 2018. Archived from the original on 11 December 2019. Retrieved 18 December 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  2. ^ a b c "Tibsovo- ivosidenib tablet, film coated". DailyMed. 24 April 2019. Archived from the original on 2 July 2019. Retrieved 18 December 2019.
  3. ^ a b c "FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma". U.S. Food and Drug Administration (FDA). 26 August 2021. Archived from the original on 26 August 2021. Retrieved 26 August 2021.
  4. ^ a b c d e f g "Ivosidenib Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 26 November 2021.
  5. ^ "Ivosidenib". SPS - Specialist Pharmacy Service. 13 December 2017. Archived from the original on 11 December 2021. Retrieved 1 December 2021.
  6. ^ "Tibsovo Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 26 February 2021. Retrieved 1 December 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Ivosidenib&oldid=1221476234"